Evolving The Retinal Landscape


Iveric Bio, An Astellas Company, is committed to developing innovative therapies that address unmet needs of patients suffering from the progressive symptoms of common and rare retinal diseases.

Innovations for Tomorrow's Retinal Disease Patients

With a diverse portfolio of therapeutic candidates at different stages of development, our pipeline is focused on bringing innovative treatments for retinal diseases to those who need them most.

For details on our pipeline, click on the programs listed below.

Therapeutics Pipeline

  • Research
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • FDA Review
  • Approved
IZERVAYTM
(avacincaptad pegol intravitreal solution)
Geographic atrophy secondary to age-related macular degeneration
Avacincaptad pegol Autosomal recessive Stargardt disease
IC-500: HtrA1 inhibitor Geographic atrophy

AAV Gene Therapy Pipeline

  • Research
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • FDA Review
mini-CEP290: LCA10 Leber congenital amaurosis type 10
mini-ABCA4: STGD1 Autosomal recessive Stargardt disease

Clinical Trials

If you are a patient that has been diagnosed with one of the diseases we are studying, please see the below links for more information about trials, or to learn more about retinal disease.

Star

The STAR trial is an ongoing phase 2b clinical trial of IZERVAY for the treatment of autosomal recessive Stargardt disease. The trial is fully enrolled with patients randomized to receive either IZERVAY or sham injection for 18 months, at which time the change in ellipsoid zone defect will be assessed by en face SD-OCT. Avacincaptad pegol is an investigational product and has not been approved by the U.S. Food and Drug Administration for autosomal recessive Stargardt disease.

View study information

Resources

Resources are available to help patients understand retinal disease or treatment information. Below are just some of these organizations.

Information for Patients
If you have been recently diagnosed with a retinal condition by your eye care professional, please visit the link below.
Learn More